论文部分内容阅读
目的骨肉瘤是好发于青少年的恶性肿瘤,预后较差。目前的化疗效果不能提高患者的5年生存率。近年来内皮抑素抑制肿瘤血管生成的作用受到重视,文中评价重组人血管内皮抑制素(恩度)治疗骨肉瘤的近期疗效和安全性。方法明确诊断为骨肉瘤的患者随机分为试验组(即恩度组)和对照组。试验组采用恩度联合化疗治疗,对照组单用化疗药物治疗,观察2组的临床受益率、生活质量评分和不良反应。结果 22例骨肉瘤患者纳入本研究。试验组和对照组的临床受益率分别为100%和71.4%,不良反应差异无统计学意义(P>0.05)。无预期以外的不良事件发生。结论初步研究结果表明,恩度对骨肉瘤显示出一定的抗肿瘤活性,安全性较好,值得进一步研究。
The purpose of osteosarcoma is a malignant tumor occurs in adolescents, the prognosis is poor. The current chemotherapy does not improve patients’ 5-year survival. In recent years, the role of endostatin in inhibiting tumor angiogenesis has received great attention. The article evaluates the short-term efficacy and safety of recombinant human endostatin (Endo) in the treatment of osteosarcoma. Methods Patients with definite diagnosis of osteosarcoma were randomly divided into experimental group (ie, Ende group) and control group. The experimental group was treated with Endo combined with chemotherapy, the control group with chemotherapy alone, the clinical benefit rate, quality of life scores and adverse reactions were observed in two groups. Results Twenty-two patients with osteosarcoma were included in this study. The clinical benefit rates of the experimental group and the control group were 100% and 71.4% respectively, with no significant difference in adverse reactions (P> 0.05). Unexpected adverse events occurred. Conclusion The preliminary results show that Endu has some anti-tumor activity on osteosarcoma, which is safe and worthy of further study.